Renovascular hypertension

C V Ram1, G P Clagett, L R Radford

  • 1Department of Internal Medicine and Surgery, University of Texas Southwestern Medical Center, Dallas 75235-8899, USA.

Insights

Renovascular hypertension, caused by renal artery stenosis, is often treated with revascularization. Surgical therapy offers the best long-term results for managing this condition.

Area of Science:

  • Nephrology
  • Cardiology
  • Hypertension Management

Background:

  • Renovascular hypertension is a common cause of secondary hypertension, but its prevalence is underestimated.
  • Advances in radiology have improved the clinical detection of renovascular hypertension.
  • Renal ischemia activates the renin-angiotensin system, leading to elevated blood pressure.

Purpose of the Study:

  • To review the causes, diagnosis, and management of renovascular hypertension.
  • To highlight the role of renal artery stenosis in blood pressure elevation.
  • To compare therapeutic options for renovascular hypertension.

Main Methods:

  • Review of pathological lesions causing renal artery stenosis (atherosclerosis and fibromuscular dysplasia).
  • Discussion of diagnostic work-up and screening for renovascular disease.
  • Analysis of management strategies including medical therapy, balloon angioplasty, and surgical revascularization.

Main Results:

  • Atherosclerosis and fibromuscular dysplasia are the primary causes of renal artery stenosis.
  • Surgical revascularization provides superior long-term outcomes compared to balloon angioplasty.
  • Medical management is increasingly limited to specific patient groups.

Conclusions:

  • Effective management of renovascular hypertension requires a multidisciplinary approach.
  • Reperfusion of the ischemic kidney is the ideal therapy to control blood pressure and prevent renal failure.
  • While balloon angioplasty is common, surgical intervention remains the gold standard for long-term results.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...